Myeloid malignancies

At the 23rd EHA Congress in Stockholm, investigators presented the latest developments in the treatment of myeloid malignancies. As an example, a novel FLT3 inhibitor for the first time demonstrated improved overall survival in AML. In addition, several presentations concerned excellent basic and translational research contributing to our understanding of the biology and pathophysiology of myeloid malignancies.

Click on the blocks below to see full presentation.

Metabolic regulation of stem cells in the bone marrow niche                       

Age related clonal hematopoiesis                                                              

Epigenetic therapy may improve graft-versus-leukemia effect                                                       

Long-term update confirms advantage of ATRA-ATO in APL                                             

Biology of cohesion-deficient myeloid malignancies                      

Next generation hypomethylating agent safe and active in MDS                          

Understanding the biology of pediatric myelodysplasia and JMML